Adding LANTUS® to oral diabetes medications (OADs) produced predictable glycemic control.
8
Not an actual patient.
|
For type 2 diabetes patients with characteristics similar to the patients studied 9:
- Mean duration of diabetes: 9.9 (± 6.8) years
- Mean BMI: 29.5 (± 3.6)
- A1C
- Mean: 8.84% (± 0.92%)
- Entry criteria: 7.5%-10.5%
|
From Janka et al.8
A 24-week, multicenter trial of patients with type 2 diabetes (N=364) compared
the efficacy and safety of adding once-daily LANTUS® basal insulin to prestudy
OADs (sulfonylurea and metformin) vs switching to twice-daily premixed insulin (human
insulin 70/30) in patients insufficiently controlled on OADs. Baseline A1C: premix
= 8.83 (± 0.87).
From Janka et al.8
From Janka et al.8
- In two additional studies, patients poorly controlled with a premix insulin regimen
experienced mean A1C reductions of 1.1% and 1.2% and mean FBG reductions of 57 to
62 mg/dL and 54 mg/dL with LANTUS® + OADs10,11
Once-daily LANTUS® + OADs produced a low rate of hypoglycemia per patient
9From Janka et al.8
IMPORTANT SAFETY INFORMATION FOR LANTUS®
LANTUS® is indicated for once-daily subcutaneous administration, at the same
time each day, for the treatment of adult and pediatric patients (6 years and older)
with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who
require basal (long-acting) insulin for the control of hyperglycemia.
LANTUS® SoloSTAR® is a disposable prefilled insulin pen. Needles and the Lantus® SoloSTAR® pen must not be shared.
LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. If mixed
or diluted, the solution may become cloudy, and the onset of action/time to peak
effect may be altered in an unpredictable manner.
LANTUS® is contraindicated in patients hypersensitive to insulin glargine or
the excipients.
Hypoglycemia is the most common adverse effect of insulin, including LANTUS®.
As with all insulins, the timing of hypoglycemia may differ among various insulin
formulations. Glucose monitoring is recommended for all patients with diabetes.
Any change of insulin type and/or regimen should be made cautiously and only under
medical supervision. Concomitant oral antidiabetes treatment may need to be adjusted.
Other adverse events commonly associated with LANTUS® include the following:
lipodystrophy, skin reactions (such as injection-site reaction, pruritus, rash),
and allergic reactions.
In clinical studies in adult patients there was a higher incidence of treatment-emergent
injection-site pain (2.7% LANTUS® vs 0.7% NPH). The reports of pain at the injection
site were usually mild and did not result in discontinuation of therapy.
Please click here for full prescribing information.
